Article Information
vol. 4 no. 10
- Received for publication February 15, 2018
- Accepted for publication September 12, 2018
- .
Author Information
- C. Ämmälä1,*,
- W. J. Drury III1,
- L. Knerr1,
- I. Ahlstedt1,
- P. Stillemark-Billton1,
- C. Wennberg-Huldt1,
- E.-M. Andersson1,
- E. Valeur1,
- R. Jansson-Löfmark1,
- D. Janzén1,
- L. Sundström2,
- J. Meuller2,
- J. Claesson2,
- P. Andersson3,
- C. Johansson3,
- R. G. Lee4,
- T. P. Prakash4,
- P. P. Seth4,*,
- B. P. Monia4 and
- S. Andersson1
- 1Cardiovascular Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 2Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 3Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
- 4Ionis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA 92010, USA.
- ↵*Corresponding author. Email: carina.ammala{at}astrazeneca.com (C.Ä.); pseth{at}ionisph.com (P.P.S.)